STOCK TITAN

EyePoint Pharmaceuticals Inc - EYPT STOCK NEWS

Welcome to our dedicated news page for EyePoint Pharmaceuticals (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EyePoint Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EyePoint Pharmaceuticals's position in the market.

Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan. The Company granted stock options to purchase up to an aggregate of 13,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The option awards have an exercise price of $19.55 per share and a ten-year term, vesting over four years. Vesting is subject to the employee’s continued service with EyePoint Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its underwritten public offering of 13,529,411 shares of common stock, grossing approximately $230.0 million. The company plans to use the net proceeds to advance clinical development of EYP-1901 for wet age-related macular degeneration and support earlier stage pipeline development initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $200.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.08%
Tags
offering
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced a public offering of $175 million of shares of common stock, with additional shares being offered to underwriters. The company plans to use the proceeds to advance clinical development for wet age-related macular degeneration and support pipeline development initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
offering
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (EYPT) announced positive Phase 2 results of its DAVIO 2 trial for its EYP-1901 treatment for wet AMD. Both doses demonstrated non-inferior change in BCVA versus aflibercept control, positive safety profile, and significant reduction in treatment burden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
177.46%
Tags
clinical trial
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan. The options allow the purchase of up to 15,000 shares of EyePoint Pharmaceuticals common stock at an exercise price of $6.69 per share. The options have a ten-year term and vest over four years, subject to the employee’s continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
none
-
Rhea-AI Summary
EyePoint Pharmaceuticals announces positive safety data for EYP-1901 in Phase 2 clinical trials. Leadership strengthened with new appointments. Topline data for trials expected in December 2023 and 2Q 2024. Financial results show total net revenue of $15.2 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.27%
Tags
earnings
-
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. will host a virtual key opinion leader (KOL) event on November 9, 2023, to discuss EYP-1901 in wet age-related macular degeneration (wet AMD) and topline data considerations for the DAVIO 2 clinical trial. The event will feature presentations from retinal experts and will be moderated by EyePoint's CEO, Jay S. Duker, M.D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
conferences
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. will present at upcoming medical meetings and an investor conference. Dr. Duker will present interim safety data for EYP-1901 with no reported serious adverse events. Dr. Avery will present preclinical data showing the neuroprotective effect of vorolanib. The presentations can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
none
EyePoint Pharmaceuticals Inc

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

1.04B
30.77M
1.02%
104.02%
11.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Watertown

About EYPT

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®